Multiple myeloma, a malignancy of plasma cells in the bone marrow, historically has posed significant treatment challenges due to its tendency to relapse. The emergence of CAR T cell therapy, where a patient’s T cells are genetically engineered to attack myeloma cells expressing the B cell maturation antigen (BCMA), has revolutionized treatment options. Ciltacabtagene autoleucel, or cilta-cel, is among the most promising of these therapies, offering hope to patients with refractory or relapsed disease. Yet, variability remains: while some patients maintain remission for years, others experience early cancer recurrence.

The research, published in the journal Blood Advances, represents the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma patients. Employing sophisticated multi-layered analyses encompassing transcriptomics, proteomics, and immune profiling, the investigators closely monitored a cohort of 19 patients enrolled in the CARTITUDE-1 clinical trial. Blood and bone marrow samples were collected at multiple time points before and after cilta-cel infusion, allowing an unprecedented resolution of immune dynamics correlated with clinical outcomes.

Findings demonstrate that long-term remission is not solely contingent on the success of the CAR T cells infused but critically depends on the intricate interplay between these engineered cells and the endogenous immune milieu. Patients who achieved durable remission beyond five years exhibited a rapid and focused expansion of CAR T cells soon after infusion. More importantly, this therapeutic effect was synergized by a broad and diverse repertoire of the patients’ own CD4+ helper T cells, which remained persistently active and functionally competent over extended periods.

Conversely, patients who relapsed earlier tended to have a higher tumor burden prior to therapy, which correlated with an immunosuppressive state characterized by elevated levels of myeloid-derived suppressor cells (MDSCs). These myeloid populations are known to blunt T cell function through various inhibitory mechanisms, effectively dampening the immune response necessary to sustain remission. The longitudinal data suggest that early myeloid suppression creates a hostile environment for CAR T cell persistence and activity, undermining long-term disease control.

The study underscores the importance of immune system preservation and diversity alongside the engineered CAR T cells. The researchers propose that maintaining a healthy and versatile helper T cell compartment is paramount for sustaining remission, as these cells support cytotoxic responses and coordinate broader immune activity. This insight opens avenues for combinatory therapeutic strategies that not only deliver potent CAR T cells but also modulate the patient’s immune landscape to reduce suppressive elements and promote T cell resilience.

Dr. Alessandro Lagana, the study’s senior author and Assistant Professor of Oncological Sciences at Mount Sinai, emphasized the transformational potential of understanding patient-specific immune dynamics. He notes that these findings could inform more precise selection criteria for CAR T therapy candidates, enable real-time monitoring for relapse through immune biomarkers, and inspire next-generation treatments aimed at fortifying the immune environment.

Mount Sinai’s multidisciplinary team plans to extend their research in larger cohorts to validate these immune signatures. A major goal is to develop a predictive blood test or biomarker panel that could non-invasively forecast which patients are most likely to achieve and maintain long-term remission. Such predictive tools would represent a leap forward in personalized cancer management, guiding therapeutic decisions with unmatched precision.

The implications of this study resonate beyond multiple myeloma, hinting that tailored immunomodulatory approaches could enhance the efficacy and durability of CAR T therapies across various hematologic malignancies. The emphasis on immune system balance and suppression also aligns with emerging paradigms from cancer immunotherapy and tumor microenvironment research.

Funding for this innovative investigation was provided by Mount Sinai’s Center of Excellence for Multiple Myeloma, with collaborative support from pharmaceutical giant Johnson & Johnson—which developed cilta-cel—and Immunai, a company specializing in advanced immune data analytics. Their combined expertise enabled the deployment of cutting-edge technologies that unraveled the complex immune interactions at play.

This landmark study redefines the way clinicians and scientists understand remission maintenance after CAR T cell therapy. It moves the paradigm from viewing CAR T cells purely as a “living drug” to recognizing the integrated ecosystem of immune factors that co-determine therapeutic success. In doing so, it lays the groundwork for future interventions that harness and preserve the full spectrum of the patient’s immune arsenal.

As CAR T cell therapy continues to evolve, the Mount Sinai team’s revelations promise to accelerate the path toward more durable, personalized cancer treatments that not only eradicate tumors but also empower the immune system’s natural capacity to sustain vigilance. The quest to achieve long-lasting cures in multiple myeloma and beyond gains new momentum through this intricate portrait of immune harmony.

Subject of Research: People

Article Title: Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid Suppression

News Publication Date: 12-Nov-2025

Web References:
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2025018078/548035/Long-term-Remission-After-Cilta-Cel-in-Multiple

References:
Blood Advances, DOI: 10.1182/bloodadvances.2025018078

Keywords: Multiple myeloma, CAR T cell therapy, cilta-cel, immune system, T cell diversity, myeloid suppression, cancer remission

The 5-HT1A receptor has long been recognized as a pivotal mediator of serotonin’s diverse effects on brain function. Despite its central role and its status as a therapeutic target for a variety of drugs—including traditional antidepressants and emerging psychedelic-based therapies—its molecular behavior has historically remained shrouded in complexity. This new research breaks through that barrier by deploying state-of-the-art cryo-electron microscopy to capture exquisitely detailed, near-atomic-resolution images of the receptor in action. These images reveal, for the first time, how the 5-HT1A receptor couples selectively with different intracellular signaling proteins called G proteins, effectively “choosing” specific pathways that determine diverse physiological outcomes.

At the heart of the study is the discovery that this receptor exhibits inherent signaling bias: it is molecularly configured to preferentially activate certain G protein subtypes over others, independent of the pharmacological agents employed to engage it. This intrinsic selectivity informs how signals are transduced inside neurons, influencing everything from emotional regulation to sensory perception. Interestingly, while drugs can modulate signal strength, they do not fundamentally alter this receptor’s pathway selectivity. For instance, the antipsychotic drug asenapine demonstrates a unique signaling profile resulting from its comparatively low receptor potency, selectively favoring one signaling route over another, thereby influencing therapeutic efficacy and side-effect profiles.

The research team combined cellular biology experiments with the cutting-edge imaging technology of cryo-electron microscopy, enabling them to visualize the dynamic interface between the receptor and G proteins in unprecedented detail. These molecular “snapshots” reveal critical contact points where the receptor’s structure intimately interacts with G protein subtypes, shedding light on how specific conformational changes in the receptor govern its signaling outcomes. These structural insights facilitate an understanding of how various pharmacological compounds can “push buttons” on this biological control panel to fine-tune neuronal responses, potentially allowing the design of drugs that selectively activate beneficial pathways while minimizing unwanted effects.

A particularly surprising and novel finding of this study is the identification of a phospholipid molecule within the cell membrane acting as an essential regulatory “co-pilot” of receptor activity. This lipid, wedged at a strategic receptor interface, influences signaling outcomes and represents a previously unrecognized layer of control. This discovery expands current paradigms surrounding receptor function, suggesting that lipid components of the neuronal membrane can play active roles in modulating receptor behavior. Such lipid-driven modulation has not been described before among the extensive family of over 700 G protein-coupled receptors (GPCRs) in humans, making this a landmark insight into membrane biology and receptor pharmacology.

The implications of these findings are profound. Traditional antidepressants targeting serotonin receptors often require weeks to exert therapeutic effects, a delay that has long puzzled clinicians and researchers alike. By delineating the molecular determinants of 5-HT1A receptor signaling and its interaction with lipids, this work lays the foundation for understanding the temporal lag in treatment response. It suggests that future drugs might be rationally designed to overcome these delays by selectively engaging signaling pathways that elicit faster therapeutic effects, transforming mental health treatment paradigms.

Moreover, the research paves a conceptual pathway toward highly tailored psychiatric medications. By mapping exactly how different ligands influence receptor conformation and downstream signaling, scientists are now equipped with a molecular blueprint to develop “precision drugs” that target only the most relevant neural circuits associated with particular symptoms. This holds promise for minimizing side effects that plague current therapies, such as sedation or metabolic disruption, potentially improving patient adherence and quality of life.

One of the lead researchers, Daniel Wacker, PhD, articulated the significance of this study, noting that the 5-HT1A receptor functions as a sophisticated control panel in the brain’s signaling machinery. According to Dr. Wacker, “Our work provides the detailed map needed to understand the switches this receptor flips, how it modulates diverse pathways, and where limitations lie. This knowledge is key for engineering next-generation mental health therapies with greater efficacy and fewer side effects.”

Audrey L. Warren, PhD, the study’s first author and now a postdoctoral fellow at Columbia University, emphasized the translational potential of these discoveries. She explained that understanding the structural “language” through which drugs ‘push buttons’ on the receptor not only predicts the therapeutic value of current compounds but also directs the design of novel molecules. “This approach marks a critical step toward classifying drugs by their precise molecular actions rather than general categories, honing treatment strategies for complex psychiatric disorders,” she elaborated.

The research team also outlined promising future directions aimed at further elucidating the mysterious role of the identified phospholipid co-factor. They plan to explore how manipulating this lipid-receptor interaction in living systems influences behavioral outcomes and drug response. Additionally, efforts are underway to translate these mechanistic insights into real-world drug candidates, building on prior successes in developing psychedelic-derived molecules with therapeutic potential.

This study is situated at the intersection of structural biology, pharmacology, and psychiatry, exemplifying how advanced experimental techniques can unravel fundamental neurobiological questions. By integrating molecular-level imaging with functional assays, the researchers have taken a decisive leap toward closing the gap between receptor dynamics and clinical therapeutics. These achievements highlight the importance of multidisciplinary research approaches in solving complex brain-related diseases, and they offer an optimistic outlook for patients suffering from debilitating mental illnesses worldwide.

In sum, revealing the 5-HT1A receptor’s selective G protein coupling, drug-dependent modulation, and unexpected lipid interactions, this study provides a comprehensive framework that could redefine how mental health drugs are developed. It charts a strategic course toward smarter, faster, and more effective treatments that address unmet clinical needs in psychiatry, promising hope for millions worldwide who struggle with mood and cognitive disorders.

Subject of Research: Cells

Article Title: Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A

News Publication Date: August 1, 2025

Web References: Science Advances Journal

References: Warren AL, Zilberg G, Abbassi A, Abraham A, Yang S, Wacker D. Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A. Science Advances. 2025.

Image Credits: From A.L Warren et al., Structural determinants of G protein subtype selectivity at the serotonin receptor 5-HT1A. Science Advances. 2025. Licensed under CC BY-NC 4.0.

Keywords: Mental health